Abstract |
Treatments aimed at inhibition of tumor necrosis factor (TNF) in patients with sepsis have been unsuccessful. Up to 50% of such patients suffer from pneumonia. To determine the effect that treatment with anti-TNF has on pneumococcal pneumonia, mice were intranasally inoculated with Streptococcus pneumoniae and, 25 h later, treated with 1 of the following: (1) control antibody, (2) anti-TNF, (3) ceftriaxone (CEF) with control antibody, or (4) CEF with anti-TNF. In the absence of treatment with CEF, mice displayed high bacterial loads in lungs, and all of these mice died within 5 days after inoculation. Anti-TNF did not influence these outcomes. In contrast, 60% of mice treated with CEF alone survived. Anti-TNF administered together with CEF reduced survival to 40% and was associated with enhanced bacterial outgrowth. These data suggest that treatment with anti-TNF impairs the therapeutic efficacy of CEF during pneumococcal pneumonia.
|
Authors | Anita W Rijneveld, Sandrine Florquin, Thomas Hartung, Peter Speelman, Tom van der Poll |
Journal | The Journal of infectious diseases
(J Infect Dis)
Vol. 188
Issue 2
Pg. 282-5
(Jul 15 2003)
ISSN: 0022-1899 [Print] United States |
PMID | 12854084
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Antibodies
- Tumor Necrosis Factor-alpha
- Ceftriaxone
|
Topics |
- Animals
- Anti-Bacterial Agents
(therapeutic use)
- Antibodies
(immunology, pharmacology)
- Ceftriaxone
(therapeutic use)
- Disease Models, Animal
- Lung
(drug effects, pathology)
- Mice
- Pneumonia, Pneumococcal
(drug therapy, pathology)
- Streptococcus pneumoniae
- Tumor Necrosis Factor-alpha
(immunology)
|